Francis I Proctor Foundation, University of California, San Francisco, CA; and.
Department of Ophthalmology, University of California, San Francisco, CA.
Cornea. 2023 Nov 1;42(11):1333-1339. doi: 10.1097/ICO.0000000000003340. Epub 2023 Jul 4.
To summarize the evidence base on the use of topical corticosteroids for infectious keratitis.
Narrative review.
Infectious keratitis is a painful condition that often results in visually significant corneal stromal scarring, even when antimicrobial therapy is successful. Corticosteroids may reduce inflammation and subsequent scar formation and while relieving the acute ocular pain associated with a corneal ulcer. However, corticosteroids also reduce the host immune response, which could hinder the ability to clear infection. The safety and effectiveness of corticosteroids depends to a large part on the efficacy of the antimicrobials being used to treat the underlying infection. Randomized trials have found that corticosteroids are safe and effective for herpetic keratitis when used with appropriate antiviral therapy, and are safe for bacterial keratitis when used with broad spectrum topical antibiotics. The effectiveness of corticosteroids for bacterial keratitis has not been shown conclusively, although more advanced bacterial corneal ulcers may do better with corticosteroids. No randomized trials have assessed the safety and effectiveness of steroids for fungal or acanthamoeba keratitis. Animal studies suggest corticosteroids may be harmful in fungal keratitis, and observational human studies have found that steroids are harmful for fungal and acanthamoeba keratitis when started prior to anti-amoebics.
Topical corticosteroids, when used as an adjunct to antimicrobial therapy, may be beneficial if the antimicrobial being used can effectively clear or suppress the infection, such as in bacterial and herpetic keratitis. Randomized trials would be helpful to further delineate the role of corticosteroids for infectious keratitis.
总结局部皮质类固醇治疗感染性角膜炎的证据基础。
叙述性综述。
感染性角膜炎是一种疼痛的疾病,即使在抗菌治疗成功的情况下,也常导致明显的角膜基质瘢痕形成。皮质类固醇可能减轻炎症和随后的瘢痕形成,并缓解与角膜溃疡相关的急性眼部疼痛。然而,皮质类固醇也会降低宿主的免疫反应,从而可能阻碍清除感染的能力。皮质类固醇的安全性和有效性在很大程度上取决于用于治疗潜在感染的抗菌药物的疗效。随机试验发现,皮质类固醇与适当的抗病毒治疗联合使用时对单纯疱疹性角膜炎是安全有效的,与广谱局部抗生素联合使用时对细菌性角膜炎是安全的。皮质类固醇治疗细菌性角膜炎的有效性尚未得到明确证实,尽管更严重的细菌性角膜溃疡可能会因皮质类固醇而受益。没有随机试验评估皮质类固醇治疗真菌或棘阿米巴角膜炎的安全性和有效性。动物研究表明皮质类固醇在真菌性角膜炎中可能有害,观察性人体研究发现,在开始使用抗阿米巴药物之前,皮质类固醇对真菌性和棘阿米巴性角膜炎有害。
局部皮质类固醇,当作为抗菌治疗的辅助治疗时,如果使用的抗菌药物能有效清除或抑制感染,如细菌性和病毒性角膜炎,可能是有益的。随机试验将有助于进一步阐明皮质类固醇在感染性角膜炎中的作用。